OLD National Bancorp IN Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

OLD National Bancorp IN cut its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 3.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,785 shares of the biopharmaceutical company’s stock after selling 817 shares during the period. OLD National Bancorp IN’s holdings in Intra-Cellular Therapies were worth $1,489,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ITCI. Signaturefd LLC lifted its position in Intra-Cellular Therapies by 85.7% during the fourth quarter. Signaturefd LLC now owns 518 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 239 shares in the last quarter. Neo Ivy Capital Management purchased a new stake in Intra-Cellular Therapies during the 3rd quarter worth $45,000. CI Investments Inc. increased its holdings in Intra-Cellular Therapies by 1,191.6% in the 3rd quarter. CI Investments Inc. now owns 1,692 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 1,561 shares in the last quarter. Global Retirement Partners LLC raised its position in Intra-Cellular Therapies by 13.8% in the third quarter. Global Retirement Partners LLC now owns 1,753 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 213 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Intra-Cellular Therapies by 95.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,465 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 1,207 shares during the period. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. TD Cowen boosted their price target on Intra-Cellular Therapies from $80.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Bank of America boosted their target price on shares of Intra-Cellular Therapies from $82.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Robert W. Baird boosted their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 17th. Finally, Mizuho boosted their target price on shares of Intra-Cellular Therapies from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $88.00.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, EVP Suresh K. Durgam sold 6,450 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the sale, the executive vice president now owns 16,170 shares in the company, valued at $1,076,275.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, EVP Suresh K. Durgam sold 6,450 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $66.56, for a total transaction of $429,312.00. Following the completion of the transaction, the executive vice president now owns 16,170 shares of the company’s stock, valued at $1,076,275.20. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Sharon Mates sold 22,590 shares of the business’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $69.79, for a total transaction of $1,576,556.10. Following the transaction, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $73,301,065.11. The disclosure for this sale can be found here. Insiders sold a total of 168,487 shares of company stock worth $11,364,950 over the last 90 days. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Trading Up 3.0 %

ITCI stock opened at $74.54 on Tuesday. Intra-Cellular Therapies, Inc. has a 1-year low of $45.50 and a 1-year high of $84.89. The firm has a fifty day moving average price of $69.34 and a two-hundred day moving average price of $64.36.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The firm had revenue of $132.10 million during the quarter, compared to analyst estimates of $135.97 million. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. The firm’s revenue for the quarter was up 50.3% compared to the same quarter last year. Equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.67 EPS for the current fiscal year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.